Results 201 to 210 of about 180,829 (383)

Supplementary Figure S5 from Targeting CD20<sup>+</sup> Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice

open access: gold, 2023
Yaya Chu   +7 more
openalex   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

open access: yesAllergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh   +7 more
wiley   +1 more source

Rituximab synergizes with hydroxyurea or vincristine in the killing of Ramos Burkitt's lymphoma B cell line [PDF]

open access: yes, 2014
Abulayha, Abdulmunem   +6 more
core   +2 more sources

Autosomal Dominant Hyper‐IgE Syndrome Patients Retain IL10‐Producing preTh17‐Cells That Are Activated by Opportunistic Pathogens and Support IgE Production

open access: yesAllergy, EarlyView.
IL‐10 producing CCR6+Th‐cells are central memory T‐cells that express ROR‐γt and differentiate to Th17‐cells via an autocrine loop of STAT3‐activating cytokines (preTh17). STAT3‐deficient AD‐HIES patients lack Th17‐ and Tfh17‐cells but retain preTh17‐ and Th1/17‐cells.
Giorgia Moschetti   +18 more
wiley   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

open access: yesBritish Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu   +3 more
wiley   +1 more source

Rapidly Progressive Cutaneous Nodules in an Elderly Woman

open access: yes
JEADV Clinical Practice, EarlyView.
Valeria Olvera‐Rodriguez   +5 more
wiley   +1 more source

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

open access: yesBritish Journal of Haematology, EarlyView.
Multivariable‐adjusted associations between family history of haematological malignancy (FHHM) and survival outcomes by non‐Hodgkin lymphoma subtype [OS (A), EFS (B), LSS (C) and failure to achieve EFS at 24 months (D)]. Subtype‐specific analyses showed that FHHM was associated with significantly inferior EFS in MCL and inferior LSS in FL.
George A. Cholack   +16 more
wiley   +1 more source

P106 | Cd20 positive multiple myeloma: is it a different entity?

open access: yesHaematologica
Introduction. Expression of CD20 antigen is generally negative in patients (pts) with multiple myeloma (MM). However, a small number of MM pts (15-20%) can show CD20 positivity on neoplastic plasma cells (PC).
Monica Poscente
doaj  

Home - About - Disclaimer - Privacy